

Special Issue

Pharmacotherapy of Macular Diseases

Message from the Guest Editor

Vascular endothelial growth factor (VEGF) plays a crucial role in retinal homeostasis and is a key factor in various macular diseases, including neovascular age-related macular degeneration, diabetic macular edema, and macular edema associated with retinal vein occlusion. It has been over 20 years since the first VEGF inhibitor (pegaptanib) was available. To date, the second-generation VEGF inhibitors, including brolucizumab, faricimab, and high-dose aflibercept, are widely used, and many retinal specialists treat these disorders using various treatment regimens. This Special Issue focuses on the treatment of these disorders, not only VEGF inhibitors but also other drugs, including steroids, etc.

Guest Editor

Dr. Yoichi Sakurada

Department of Ophthalmology, University of Yamanashi, Chuo 409-3898, Japan

Deadline for manuscript submissions

20 February 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/251754

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)